ESSA Pharma Inc. (EPIX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Vancouver, BC, カナダ. 現CEOは David Ross Parkinson.
EPIX を有する IPO日 2015-03-13, 35 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $9.52M.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
